Further studies on the use of EphA2 targeting agents such as YNH or 123B9 to direct chemotherapy to pancreatic cancers is therefore warranted to devise innovative and perhaps more effective therapies for this invariably fatal and aggressive cancer. Here, EPHA2 is linked to pancreatic neoplasm.